Patents Assigned to SmithKline Beecham p.l.c.
  • Use of orexin receptor antagonists
    Patent number: 6506774
    Abstract: The use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: January 14, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Elaine Alison Irving, Gareth John Sanger
  • Medicament
    Publication number: 20030004201
    Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the prevention of atheroma progression and the regression of atheroma.
    Type: Application
    Filed: April 29, 2002
    Publication date: January 2, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventor: James Hill
  • Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
    Publication number: 20020193575
    Abstract: Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.
    Type: Application
    Filed: June 12, 2001
    Publication date: December 19, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Stephen Dudley Holmes, Mitchell Stuart Gross, Daniel R. Sylvester
  • Multi-limbed reaction vessel
    Patent number: 6491874
    Abstract: A laboratory vessel comprising two substantially cylindrical chambers with parallel longitudinal axes between their bottom and mouth openings and lower and upper conduits linking the chambers so that he contents of the vessel can flow between the first and second chambers via the upper and lower conduits. The vessel is particularly suited for use with automated reactor systems.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: December 10, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Gillian Elizabeth Smith, Kenneth Thomas Veal
  • Substituted isoquinoline derivatives and their use as anticonvulsivants
    Patent number: 6492378
    Abstract: This invention relates to novel substituted isoquinoline derivatives and their use as anticonvulsants.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: December 10, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: John David Harling, Jag Paul Heer, Mervyn Thompson
  • Substituted isoquinoline derivatives and their use as inticonvulsants
    Patent number: 6492388
    Abstract: The invention relates to novel isoquinolines and their use as anticonvulsants and in the treatment of a variety of disorders.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: December 10, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: John David Harling, Mervyn Thompson
  • Use of benzopyranols to treat neurological disorders
    Patent number: 6492415
    Abstract: Benzopyran derivatives and analogs are disclosed as useful for the treatment and/or prophylaxis of neuralgia, trigeminal neuralgia, neuropathic pain, dental pain and cancer pain.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: December 10, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Andrew Parsons, Mervyn Thompson, Neil Upton, John Morris Evans
  • Composition
    Patent number: 6486106
    Abstract: A skin wash composition intended for topical application to water-wetted skin comprising an &agr;-hydroxy acid active ingredient formulated in a mild and non-irritant detergent base consisting of a mixture of a non-ionic alkypolyglucoside surfactant and an amphoteric surfactant.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: November 26, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Lynda Rosemary Charlton, Juliet Teresa McGillycuddy, Sharon Owen
  • Process for epoxidizing substituted cyclohexanones
    Patent number: 6482960
    Abstract: This invention relates to a method for preparing 1-oxaspiro[2,5]-carbonitriles from ketones using spinning disc reactor technology.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: November 19, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Clemens Michael Helmut Brechtelsbauer, Paul Oxley
  • Process for the preparation of anti-malarial drugs
    Patent number: 6479660
    Abstract: The invention relates to novel intermediates and processes for the preparation of quinoline compounds useful as anti-malarial drugs and novel intermediates useful in the process. A process for the preparation of a compound of formula (I) in which R1 is C1-6 alkyl; R2 and R3 are independently hydrogen, halogen, trifluoromethyl or C1-6 alkoxy; R4 is C1-6 alkyl; R5 is hydrogen or C1-6 alkyl; and R6 or amino which comprises reacting a compound of formula (II) in which R1, R4 and R5 are as defined in formula (I) and X is a leading group with a compound of formula (III).
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: November 12, 2002
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham Corporation
    Inventors: Cletus Onwuzurike Ugwuegbulam, James Edward Foy
  • Compounds and methods
    Patent number: 6476028
    Abstract: A method of treating a CCR5-mediated disease state in mammals which comprises administering to a mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 8, 2000
    Date of Patent: November 5, 2002
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: William E. Bondinell, James Chan, Roderick A. Porter, Joseph W. Venslavsky, Steven Dabbs, David T. Davies
  • Pharmaceutical formulations
    Patent number: 6472383
    Abstract: A pharmaceutical formulation comprises, in combination with a penem of formula (I): in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula:  wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier; a &bgr;-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: October 29, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Kenneth Coleman, Jane Elizabeth Neale
  • Method of treatment
    Publication number: 20020156093
    Abstract: The use of [R-(Z)]-&agr;-(methoxyimino)-&agr;-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile or a pharmaceutically acceptable salt thereof for the treatment of psychosis or other neuropsychiatric symptoms.
    Type: Application
    Filed: April 17, 2002
    Publication date: October 24, 2002
    Applicant: SmithKline Beecham Corporation & SmithKline Beecham p.l.c.
    Inventors: Frank Brown, James P. Mc Cafferty, Eve Naomi Cedar
  • Use of insulin sensitisers for treating renal diseases
    Publication number: 20020156106
    Abstract: A method of treatment and/or prophylaxis of renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease, and micoralbuminuria which comprises the administration of an effective, non-toxic amount of an insulin sensitizer to a human or non-human mammal in need thereof.
    Type: Application
    Filed: April 22, 2002
    Publication date: October 24, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Robin Edwin Buckingham
  • Controlled release dosage form of [R-(Z)]-&agr;-(methoxyimino)-&agr;-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride
    Patent number: 6468560
    Abstract: A controlled release formulation of an acetonitrile compound and its use in the treatment and/or prophylaxis of certain disorders.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: October 22, 2002
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham Corporation
    Inventors: Joseph Peter Sauer, Susan Marie Milosovich, William Thomas Muldoon, James Albert Napper, Laurence Rousseau
  • Process for preparing solid dosage forms of very low-dose drugs
    Publication number: 20020150618
    Abstract: A drug formulation process which comprises admixing carrier particles with a solution of drug in water in a quantity of 1-3% by weight of solution to total mix and a method of treatment and/or prophylaxis of dementia, which method comprises administering to the patient [R-(Z)]-&agr;-(methoxyimino)-&agr;-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride at a daily dose below 0.01 mg/kg and pharmaceutical compositions used therein.
    Type: Application
    Filed: June 10, 2002
    Publication date: October 17, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: James Albert Napper, Karen Triona O'Brien, Sultan James Manek, Rajinder Kumar, Julia Mary Loudon, Michael Sydney George Clark, Neil Mortimer
  • Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
    Patent number: 6465485
    Abstract: Compounds of formula (I): and their salts having affinity for dopamine receptors, in particular the D3 receptor, and thus potential in the treatment of conditions wherein modulation of the D3 receptor is beneficial, e.g., as antipsychotic agents.
    Type: Grant
    Filed: September 6, 2000
    Date of Patent: October 15, 2002
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Clive Leslie Branch, Christopher Norbert Johnson, Geoffrey Stemp
  • Treatment of diabetes with thiazolidinedione and sulphonylurea
    Publication number: 20020147226
    Abstract: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and an insulin secretagogue, to a mammal in need thereof.
    Type: Application
    Filed: March 21, 2002
    Publication date: October 10, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Stephen Alistair Smith
  • 2-(pyrazol-3-yl)carbapenem derivatives
    Publication number: 20020147333
    Abstract: A compound of formula (I): 1
    Type: Application
    Filed: January 23, 2002
    Publication date: October 10, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Eric Hunt, Steven Coulton, Jeremy David Hinks, Stephen Frederick Moss, Stephen Christopher Martin Fell, Alfred John Eglington, George Burton
  • Molecular cloning of a 7TM receptor (AxOR34) and screening methods thereof
    Patent number: 6461836
    Abstract: AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: October 8, 2002
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Nabil Elshourbagy, Usman Shabon, Robert S. Ames, Henry S. Sarau, Lisa Vawter, David Michalovich